France
MELLIsim is an innovative health care startup founded in 2019 with the aim of addressing the unmet needs of Type 2 Diabetic (T2D) patients through its revolutionary solution, MELLIsense CGM (Continuous Glucose Monitoring). The company has collaborated with ITODYS, a leading electrochemical biosensors research lab in France, to develop cutting-edge glucose sensor technology.
By introducing a wearable biosensor patch linked to a proprietary Artificial Intelligence application on the patient's smartphone, MELLIsense aims to replace the painful and cumbersome finger-prick glucose measurements, providing a more comfortable and continuous monitoring solution for T2D patients.
What sets MELLIsim apart is not only its innovative technology but also its unique combination of clinical diabetes specialists’ knowledge and personalized analyses and recommendations, along with the guidance from a personal diabetes coach. The company's collaboration with renowned hospital specialists and patient associations in France, Switzerland, UK, and Canada, further enhances its credibility and reach.
One of the key differentiators for MELLIsense is its pricing strategy, aiming to price the solution similarly to the current practice with BGM (Blood Glucose Measurement) finger-pricking methods, making it 2 to 8 times cheaper than most competitor CGM solutions.
MELLIsim has already validated the effectiveness of its strategy with human trials in 2018 and pre-clinical trials in 2019. Currently, the focus is on the sensor's miniaturization and the automation of the manufacturing process, with plans for the first in-human acute tests of the sensor in 2020 and continued clinical trials in 2022. The company aims to obtain FDA approval and the CE mark by Q2 2023 and provide T2D patients with the complete MELLIsense solution by the end of 2023.
MELLIsim is now seeking investors, industrial, and distribution partners to support its mission of revolutionizing the care of T2D patients globally.
